Donald R. Miller, ScD

home / authors / donald-r-miller-scd

Articles

November 16th 2018

Overdose Risk for Veterans Receiving Opioids From Multiple Sources

Guneet K. Jasuja, PhD Omid Ameli, MD, MPH Donald R. Miller, ScD Thomas Land, PhD Dana Bernson, MPH Adam J. Rose, MD, MSc Dan R. Berlowitz, MD, MPH David A. Smelson, PsyD

Among veterans in Massachusetts, receipt of opioids from multiple sources, with or without benzodiazepines, was associated with worse opioid-related outcomes.

March 15th 2018

Trends in Opioid and Nonsteroidal Anti-Inflammatory Use and Adverse Events

Veronica Fassio, PharmD Sherrie L. Aspinall, PharmD, MSc Xinhua Zhao, PhD Donald R. Miller, ScD Jasvinder A. Singh, MD, MPH Chester B. Good, MD, MPH Francesca E. Cunningham, PharmD

Opioid use incidence and prevalence rates decreased with implementation of an opioid safety initiative, whereas nonsteroidal anti-inflammatory drug rates remained constant. Rates of adverse events were higher among opioid users.

March 14th 2011

Outpatient Wait Time and Diabetes Care Quality Improvement

Julia C. Prentice, PhD B. Graeme Fincke, MD Donald R. Miller, ScD Steven D. Pizer, PhD

Longer primary care wait times were associated with small increases in glycated hemoglobin levels. Diabetes care quality improvement strategies should consider timely access to care.

April 2nd 2009

Does Opioid Therapy Affect Quality of Care for Diabetes Mellitus?

Adam J. Rose, MD, MSc John A. Hermos, MD Susan M. Frayne, MD, MPH Leonard M. Pogach, MD, MBA Dan R. Berlowitz, MD, MPH Donald R. Miller, ScD

Within the Veterans Affairs system, diabetes performance measures were similar in patients who received chronic opioid therapy and in those who did not.

August 1st 2007

Who Should Receive Optimal Diabetes Care?

Gail M. Amundson, MD George J. Isham, MD Reply by Leonard M. Pogach, MD, MBA David Aron, MD Donald R. Miller, ScD

March 1st 2007

Should Mitigating Comorbidities Be Considered in Assessing Healthcare Plan Performance in Achieving Optimal Glycemic Control?

Leonard M. Pogach, MD, MBA Anjali Tiwari, MS Miriam Maney, MS Mangala Rajan, MBA Donald R. Miller, ScD David Aron, MD

February 1st 2007

Facility Variation in Utilization of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes Mellitus and Chronic Kidney Disease

Anjali Tiwari, MBBS, MS Chin-Lin Tseng, DrPH Elizabeth F. O. Kern, MD Miriam Maney, MA, CHPQ Donald R. Miller, ScD Leonard Pogach, MD, MBA